Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 1128-1139

  Natsubori, Tatsunobu ^a   Inoue, Hideyuki ^a   Abe, Osamu ^a,b   Takano, Yosuke ^a   Iwashiro, Norichika ^a   Aoki, Yuta ^a   Koike, Shinsuke ^a   Yahata, Noriaki ^a   Katsura, Masaki ^a   Gonoi, Wataru ^a   Sasaki, Hiroki ^a   Takao, Hidemasa ^a   Kasai, Kiyoto ^a   Yamasue, Hidenori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anterior cingulate cortex; At risk mental state; Biomarkers; Frontal lobe; Magnetic resonance imaging; Neurochemical abnormality

Indexed keywords

GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; AMINO ACID BRAIN LEVEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EXCITOTOXICITY; FEMALE; FRONTAL CORTEX; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLITE; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE SCANNER; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA; ADOLESCENT; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; DISEASE COURSE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRODROMAL SYMPTOM; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; ASPARTIC ACID; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84907375396     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt124     Document Type: Article

References (85)

1. Stone JM, Day F, Tsagaraki H, et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry. 2009;66: 533-539.
2. Jessen F, Scherk H, Träber F, et al. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr Res. 2006;87: 81-88.
3. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69: 220-229.
4. Koike S, Takano Y, Iwashiro N, et al. A multimodal approach to investigate biomarkers for psychosis in a clinical setting: the integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project. Schizophr Res. 2013;143: 116-124.
5. Smieskova R, Fusar-Poli P, Allen P, et al. Neuroimaging predictors of transition to psychosis-A systematic review and meta-analysis. Neurosci Biobehav Rev. 2010;34: 1207-1222.
6. Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry. 2011;70: 88-96.
7. Hirayasu Y, Shenton ME, Salisbury DF, et al. Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry. 1998;155: 1384-1391.
8. Kasai K, Shenton ME, Salisbury DF, et al. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry. 2003;60: 766-775.
9. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a crosssectional and longitudinal MRI comparison. Lancet. 2003;361: 281-288.
10. Suzuki M, Zhou SY, Takahashi T, et al. Differential contributions of prefrontal and temporolimbic pathology to mechanisms of psychosis. Brain. 2005;128: 2109-2122.
11. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport. 1996;7: 1397-1400.
12. Lentz MR, Kim JP, Westmoreland SV, et al. Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology. 2005;235: 461-468.
13. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10: 900-919.
14. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007;81: 89-131.
15. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1h-MRS studies. Schizophr Bull. 2013;39: 120-129.
16. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 2001;11: 327-335.
17. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7: 39-47.
18. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann N Y Acad Sci. 1996;777: 380-387.
19. Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2002;8: 562-573.
20. Krystal JH. Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia. Biol Psychiatry. 2008;64: 358-360.
21. Stone JM, Howes OD, Egerton A, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry. 2010;68: 599-602.
22. Fusar-Poli P, Stone JM, Broome MR, et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry. 2011;68: 881-890.
23. Wood SJ, Yücel M, Wellard RM, et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res. 2007;94: 328-331.
24. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and metaanalysis. Neuropsychopharmacology. 2005;30: 1949-1962.
25. Brugger S, Davis JM, Leucht S, Stone JM. Proton magnetic resonance spectroscopy and illness stage in schizophrenia- a systematic review and meta-analysis. Biol Psychiatry. 2011;69: 495-503.
26. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res. 2012;203: 111-125.
27. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60: 21-32.
28. De la Fuente-Sandoval C, Leon-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011;36: 1781-1791.
29. Bustillo JR, Rowland LM, Jung R, et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology. 2008;33: 2456-2466.
30. Théberge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007;191: 325-334.
31. Yang S, Hu J, Kou Z, Yang Y. Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T. Magn Reson Med. 2008;59: 236-244.
32. Jensen JE, Licata SC, Ongür D, et al. Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed. 2009;22: 762-769.
33. Henry ME, Lauriat TL, Shanahan M, Renshaw PF, Jensen JE. Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4 Tesla. J Magn Reson. 2011;208: 210-218.
34. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Non-patient Edition. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1997 (Japanese translation: Kitamura T, Okano T. Tokyo, Japan: Nihon Hyoronsha Publishers; 2003).
35. Iwashiro N, Suga M, Takano Y, et al. Localized gray matter volume reductions in the pars triangularis of the inferior frontal gyrus in individuals at clinical high-risk for psychosis and first episode for schizophrenia. Schizophr Res. 2012;137: 124-131.
36. McGlashan TH, Miller TJ, Woods SW. Structured Interview for Prodromal Syndromes (Version 3.0). New Haven, CT: PRIME Research Clinic, Yale School of Medicine; 2001.
37. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276.
38. Barneveld PS, Pieterse J, de Sonneville L, et al. Overlap of autistic and schizotypal traits in adolescents with autism spectrum disorders. Schizophr Res. 2011;126: 231-236.
39. Solomon M, Olsen E, Niendam T, et al. From lumping to splitting and back again: atypical social and language development in individuals with clinical-high-risk for psychosis, first episode schizophrenia, and autism spectrum disorders. Schizophr Res. 2011;131: 146-151.
40. Aoki Y, Kasai K, Yamasue H. Age-related change in brain metabolite abnormalities in autism: a meta-analysis of proton magnetic resonance spectroscopy studies. Transl Psychiatry. 2012;2: e69.
41. Brans RG, van Haren NE, van Baal GC, Schnack HG, Kahn RS, Hulshoff Pol HE. Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia. Arch Gen Psychiatry. 2008;65: 1259-1268.
42. Hollingshead AB. Two Factor Index of Social Position. New Haven, CT: Yale Univ Press; 1965.
43. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9: 97-113.
44. Matsuoka K, Uno M, Kasai K, Koyama K, Kim Y. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin Neurosci. 2006;60: 332-339.
45. Uetsuki M, Matsuoka K, Kim Y, et al. Estimation of premorbid IQ by JART in schizophrenia. Seishin Igaku. 2006;48: 15-22.
46. Aoki Y, Abe O, Yahata N, et al. Absence of age-related prefrontal NAA change in adults with autism spectrum disorders. Transl Psychiatry. 2012;2: e178.
47. Yamasue H, Fukui T, Fukuda R, et al. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport. 2002;13: 2133-2137.
48. Lutkenhoff ES, van Erp TG, Thomas MA, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010;15: 308-318.
49. Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology. 2012;37: 2635-2642.
50. Reid MA, Stoeckel LE, White DM, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2010;68: 625-633.
51. Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex ?-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69: 449-459.
52. Walter M, Henning A, Grimm S, et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry. 2009;66: 478-486.
53. Waddell KW, Zanjanipour P, Pradhan S, et al. Anterior cingulate and cerebellar GABA and Glu correlations measured by 1h J-difference spectroscopy. Magn Reson Imaging. 2011;29: 19-24.
54. Tal A, Kirov II, Grossman RI, Gonen O. The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed. 2012;25: 1392-1400.
55. O'Neill J, Levitt J, Caplan R, et al. 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. Neuroimage. 2004;21: 1781-1789.
56. Bustillo JR, Rowland LM, Mullins P, et al. 1H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010;15: 629-636.
57. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54: 959-965.
58. Théberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159: 1944-1946.
59. Bertolino A, Sciota D, Brudaglio F, et al. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry. 2003;160: 483-489.
60. Fannon D, Simmons A, Tennakoon L, et al. Selective deficit of hippocampal N-acetylaspartate in antipsychotic- naive patients with schizophrenia. Biol Psychiatry. 2003;54: 587-598.
61. Yasukawa R, Miyaoka T, Mizuno S, et al. Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). J Psychiatry Neurosci. 2005;30: 416-422.
62. Ohrmann P, Kugel H, Bauer J, et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr Res. 2008;106: 156-163.
63. Thomas MA, Ke Y, Levitt J, et al. Preliminary study of frontal lobe 1H MR spectroscopy in childhood-onset schizophrenia. J Magn Reson Imaging. 1998;8: 841-846.
64. Egerton A, Brugger S, Raffin M, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37: 2515-2521.
65. Velakoulis D, Wood SJ, Smith DJ, et al. Increased duration of illness is associated with reduced volume in right medial temporal/ anterior cingulate grey matter in patients with chronic schizophrenia. Schizophr Res. 2002;57: 43-49.
66. Koo MS, Levitt JJ, Salisbury DF, Nakamura M, Shenton ME, McCarley RW. A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis. Arch Gen Psychiatry. 2008;65: 746-760.
67. Premkumar P, Fannon D, Kuipers E, Cooke MA, Simmons A, Kumari V. Association between a longer duration of illness, age and lower frontal lobe grey matter volume in schizophrenia. Behav Brain Res. 2008;193: 132-139.
68. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52: 998-1007.
69. McCarley RW, Hsiao JK, Freedman R, Pfefferbaum A, Donchin E. Neuroimaging and the cognitive neuroscience of schizophrenia. Schizophr Bull. 1996;22: 703-725.
70. Clark JF, Doepke A, Filosa JA, et al. N-acetylaspartate as a reservoir for glutamate. Med Hypotheses. 2006;67: 506-512.
71. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122 (Pt 4): 593-624.
72. Meyer-Lindenberg A. Neuroimaging and the question of neurodegeneration in schizophrenia. Prog Neurobiol. 2011;95: 514-516.
73. Kim H, McGrath BM, Silverstone PH. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders-focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol. 2005;20: 309-326.
74. Yoo SY, Yeon S, Choi CH, et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res. 2009;111: 86-93.
75. Sijens PE, Knopp MV, Brunetti A, et al. 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med. 1995;33: 818-826.
76. Moore CM, Bonello CM, Sherwood AR, Cohen BM, Renshaw PF, Yurgulen-Todd DA. Mesial temporal lobe Cho to Cr(PCr) ratio asymmetry in chronic schizophrenics. Schizophr Res. 2002;57: 35-42.
77. Szulc A, Galinska B, Tarasow E, et al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry. 2005; 38: 214-219.
78. Szulc A, Galinska B, Tarasow E, et al. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry. 2011;44: 148-157.
79. Goto N, Yoshimura R, Kakeda S, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat. 2012;8: 119-122.
80. Qayyum A. MR spectroscopy of the liver: principles and clinical applications. Radiographics 2009;29: 1653-1664.
81. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69: 562-571.
82. Wijtenburg SA, Knight-Scott J. Very short echo time improves the precision of glutamate detection at 3T in 1H magnetic resonance spectroscopy. J Magn Reson Imaging. 2011;34: 645-652.
83. Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med. 2008;60: 964-969.
84. Seeger U, Klose U, Mader I, et al. Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn Reson Med. 2003;49: 19-28.
85. Auer DP, Gossl C, Schirmer T, et al. Improved analysis of 1H-MR spectra in the presence of mobile lipids. Magn Reson Med. 2001;46: 615-618.